AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 32196898 — intervention group
Group type: COMPARATOR
Intervention: Inpatient group
Number of subjects: 117
Study 35504178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 199
Study 35504178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 199
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication dispensing errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescription related errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist counselling errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrong quantity errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Wrong drug errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Causes of errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of errors
Number of subjects: 350
Study 32803560 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of errors
Number of subjects: 350
Study 34217774 — intervention group
Group type: EXPERIMENTAL
Intervention: semaglutide 1.0 mg
Number of subjects: 25
Study 34217774 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 25
Study 32439543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus fermentum (N2, N7) and Lactobacillus plantarum (N20)
Number of subjects: 120
Study 32439543 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus strains
Number of subjects: 120
Study 35176755 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (arm A, TAMOX/VOR)
Number of subjects: 31
Study 35176755 — intervention group
Group type: COMPARATOR
Intervention: Vorinostat (arm B, VOR)
Number of subjects: 31
Study 33215533 — intervention group
Group type: COMPARATOR
Intervention: Commercial control soy formula (SF)
Number of subjects: 71
Study 33215533 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially hydrolyzed SF (10% hydrolyzed)
Number of subjects: 71
Study 33215533 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hydrolyzed SF
Number of subjects: 71
Study 33173165 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to standard adjuvant chemotherapy (FOFOX or XELOX)
Number of subjects: 3451
Study 33173165 — intervention group
Group type: COMPARATOR
Intervention: Standard adjuvant chemotherapy (FOFOX or XELOX) without bevacizumab
Number of subjects: 3451
Study 616120246 — intervention group
Group type: EXPERIMENTAL
Intervention: Triamcinolone Assisted Vitrectomy (VAT)
Number of subjects: 24
Study 35228783 — intervention group
Group type: EXPERIMENTAL
Intervention: Cap. Torchnil & Tab. Febcin (Add-on Group)
Number of subjects: 150
Study 35228783 — intervention group
Group type: COMPARATOR
Intervention: SOC (SOC Group)
Number of subjects: 150
Study 32958269 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-only fasting for 24 hours before and 24 hours after each chemotherapy cycle
Number of subjects: 20
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB)
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) after enrolment
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) in TNBC
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) in RAM arm
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) after enrolment in RAM arm
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) and treatment-emergent hypertension
Number of subjects: 1144
Study 616063474 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-adrenergic blockers (BB) and treatment arm interaction
Number of subjects: 1144
Study 34510652 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraine (any migraine, migraine with aura, migraine without aura)
Number of subjects: 0
Study 32593322 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitor dapagliflozin
Number of subjects: 0
Study 34028551 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study 34028551 — intervention group
Group type: COMPARATOR
Intervention: Cabazitaxel
Number of subjects: 0
Study 33023132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention program (PREDIMED-Plus trial)
Number of subjects: 5695
Study 34332617 — intervention group
Group type: EXPERIMENTAL
Intervention: ACLS + REBOA
Number of subjects: 200
Study 34332617 — intervention group
Group type: COMPARATOR
Intervention: ACLS
Number of subjects: 200
Study 32115111 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block (TB) appliance
Number of subjects: 25
Study 32115111 — intervention group
Group type: COMPARATOR
Intervention: sagittal-guidance Twin-block (SGTB) appliance
Number of subjects: 25
Study 34226218 — intervention group
Group type: EXPERIMENTAL
Intervention: Microablative fractional radiofrequency (MAFRF) treatment
Number of subjects: 0
Study 34226218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal oestrogens
Number of subjects: 0
Study 34226218 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study 32573523 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 83
Study 32573523 — intervention group
Group type: COMPARATOR
Intervention: Conventional cardiovascular rehabilitation (CCVR)
Number of subjects: 83
Study 36495107 — intervention group
Group type: EXPERIMENTAL
Intervention: Sling exercises combined with targeted vibration and oscillations (SE + VO)
Number of subjects: 36
Study 36495107 — intervention group
Group type: COMPARATOR
Intervention: Sling exercises (SE)
Number of subjects: 36
Study 33955835 — intervention group
Group type: EXPERIMENTAL
Intervention: VR cognitive training (multidomain and neuropsychologist-assisted) in a fully immersive VR environment, twice a week for 1 month
Number of subjects: 41
Study 33955835 — intervention group
Group type: EXPERIMENTAL
Intervention: VR cognitive training
Number of subjects: 41
Study 33955835 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual therapy such as pharmacotherapy)
Number of subjects: 41
Study 32602000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination method using CEUS and blue dye (BD)
Number of subjects: 134
Study 32602000 — intervention group
Group type: COMPARATOR
Intervention: Single blue dye (BD) method
Number of subjects: 134
Study 34159732 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectus sheath block (RSB) with 10 mL of 0.375% ropivacaine
Number of subjects: 62
Study 34159732 — intervention group
Group type: COMPARATOR
Intervention: Local anesthesia (LA) with subcutaneous and fascial injection of 10 mL of 0.75% ropivacaine
Number of subjects: 62
Study 34790535 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon capsule endoscopy (CCE)
Number of subjects: 234
Study 33152308 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoradiotherapy
Number of subjects: 0
Study 33152308 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance chemotherapy after chemoradiotherapy
Number of subjects: 0
Study 35000693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Goal Setting
Number of subjects: 512
Study 35000693 — intervention group
Group type: COMPARATOR
Intervention: Static Goal Setting
Number of subjects: 512
Study 35000693 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Reinforcement
Number of subjects: 512
Study 35000693 — intervention group
Group type: COMPARATOR
Intervention: Delayed Reinforcement
Number of subjects: 512
Study 35000693 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive Goals + Immediate Reinforcement
Number of subjects: 512
Study 35000693 — intervention group
Group type: COMPARATOR
Intervention: Static Reinforcement
Number of subjects: 512
Study 32179241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins 320 mg/day
Number of subjects: 169
Study 32179241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins 40 mg/day
Number of subjects: 169
Study 32179241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins 80 mg/day
Number of subjects: 169
Study 32179241 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins (all doses)
Number of subjects: 169
Study 35653981 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus cetuximab with binimetinib
Number of subjects: 0
Study 35653981 — intervention group
Group type: EXPERIMENTAL
Intervention: Encorafenib plus cetuximab without binimetinib
Number of subjects: 0
Study 35653981 — intervention group
Group type: COMPARATOR
Intervention: Control (irinotecan plus cetuximab or FOLFIRI plus cetuximab)
Number of subjects: 0
Study 33603778 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower limb CIMT with 600 repetitions (group 1)
Number of subjects: 58
Study 33603778 — intervention group
Group type: COMPARATOR
Intervention: Lower limb CIMT with 3 hours of task practice (group 2)
Number of subjects: 58
Study 32041913 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciplukan extract 3 x 250 mg/day for 12 weeks
Number of subjects: 59
Study 32041913 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 36039973 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion-based exercises
Number of subjects: 90
Study 36039973 — intervention group
Group type: EXPERIMENTAL
Intervention: Extension-based exercises
Number of subjects: 90
Study 36039973 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study 34425791 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation model of care
Number of subjects: 950
Study 34425791 — intervention group
Group type: EXPERIMENTAL
Intervention: Capitation payment formula
Number of subjects: 950
Study 34425791 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reflection methodology
Number of subjects: 950
Study 34048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone accessibility features
Number of subjects: 570
Study 34048330 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparative analysis by disability type and phone type
Number of subjects: 570
Study 33254048 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive pictures
Number of subjects: 178
Study 33254048 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pictures
Number of subjects: 178
Study 33254048 — intervention group
Group type: COMPARATOR
Intervention: Exposure only condition (looking at a cross)
Number of subjects: 178
Study 34639282 — intervention group
Group type: EXPERIMENTAL
Intervention: IBCT-based conflict prevention program (5 sessions of 120 minutes each)
Number of subjects: 6
Study 34639282 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 6
Study 36181377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (8 mg∙kg−1)
Number of subjects: 40
Study 36181377 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg∙kg−1 and 4 mg∙kg−1)
Number of subjects: 40
Study 36181377 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine (0.03 mg∙kg−1)
Number of subjects: 40
Study 33377792 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective observational study (POS)
Number of subjects: 4033
Study 33377792 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective cohort study (RCS)
Number of subjects: 4033
Study 33377792 — intervention group
Group type: COMPARATOR
Intervention: Randomized clinical trial (RCT)
Number of subjects: 4033
Study 35892247 — intervention group
Group type: EXPERIMENTAL
Intervention: Efgartigimod
Number of subjects: 0
Study 35892247 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32538746 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE in combination with lobaplatin
Number of subjects: 0
Study 32538746 — intervention group
Group type: COMPARATOR
Intervention: TACE in combination with cisplatin (Control group)
Number of subjects: 0
Study 35506388 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 448
Study 35506388 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydropyridine calcium channel blockers
Number of subjects: 448
Study 35506388 — intervention group
Group type: COMPARATOR
Intervention: Intensive blood pressure arm
Number of subjects: 448
Study 35506388 — intervention group
Group type: EXPERIMENTAL
Intervention: Top tertile of WMH progression
Number of subjects: 448
Study 33057999 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-directed replacement (any choice of steroid, dose or route)
Number of subjects: 60
Study 33057999 — intervention group
Group type: COMPARATOR
Intervention: Fixed-dose dexamethasone 8 mg oral before starting docetaxel
Number of subjects: 60
Study 34694223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FC; 1,000 mg, single dose)
Number of subjects: 104
Study 34694223 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS; 200 mg every 48 hours until covering the total iron deficit or discharge)
Number of subjects: 104
Study 34694223 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose (FC)
Number of subjects: 104
Study 34694223 — intervention group
Group type: COMPARATOR
Intervention: Iron sucrose (IS)
Number of subjects: 104
Study 34853109 — intervention group
Group type: EXPERIMENTAL
Intervention: Perineural catheter (PNC) for postoperative pain relief
Number of subjects: 14
Study 34853109 — intervention group
Group type: COMPARATOR
Intervention: Standard care for postoperative pain relief
Number of subjects: 14
Study 32053119 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (CARE+ Corrections), participants received weekly or daily SMS text messages for 6 months.
Number of subjects: 110
Study 32053119 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS text messaging intervention (CARE+ Corrections) with customized message content.
Number of subjects: 110
Study 32053119 — intervention group
Group type: COMPARATOR
Intervention: Control group (no SMS text messaging intervention).
Number of subjects: 110
Study 33538999 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients' Own Medicines (POMs)
Number of subjects: 30
Study 33538999 — intervention group
Group type: COMPARATOR
Intervention: Usual dispensing (Control)
Number of subjects: 30
Study 34586476 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic DCR with silicone stent tube (SST)
Number of subjects: 60
Study 34586476 — intervention group
Group type: COMPARATOR
Intervention: Endoscopic DCR without silicone stent tube (NSST)
Number of subjects: 60
Study 34151513 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed model (LMM) on log-transformed biomarkers
Number of subjects: 0
Study 34151513 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear mixed model (LMM)
Number of subjects: 0
Study 34151513 — intervention group
Group type: EXPERIMENTAL
Intervention: Proposed model
Number of subjects: 0
Study 32883807 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program (prenatal and postpartum nutrition counseling and nutrition parenting support groups)
Number of subjects: 566
Study 32883807 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 566
Study 32883807 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program (with varying attendance)
Number of subjects: 566
Study 32883807 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting Early Program
Number of subjects: 566
Study 37560168 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based rehabilitation program using a mobile app
Number of subjects: 50
Study 37560168 — intervention group
Group type: COMPARATOR
Intervention: Home-based rehabilitation program using an exercise pamphlet
Number of subjects: 50
Study 35081422 — intervention group
Group type: EXPERIMENTAL
Intervention: pRMGIC (30% ethylene glycol methacrylate phosphate)
Number of subjects: 192
Study 35081422 — intervention group
Group type: COMPARATOR
Intervention: Fuji II LC (control)
Number of subjects: 192
Study 35081422 — intervention group
Group type: EXPERIMENTAL
Intervention: pRMGIC
Number of subjects: 192
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: High BMI
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Short stature
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Male offspring
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower wealth
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower husband's education
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Age and parity
Number of subjects: 14261
Study 33452758 — intervention group
Group type: EXPERIMENTAL
Intervention: Socio-economic status
Number of subjects: 14261
Study 32213517 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group cognitive-behavioural therapy (CBT) programme
Number of subjects: 99
Study 32213517 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (control group)
Number of subjects: 99
Study 33714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital post analogs of 0.9 mm, 1.0 mm, and 1.14 mm in diameter at depths of 3 mm, 4 mm, and 5 mm from the radiographic apex
Number of subjects: 122
Study 33714551 — intervention group
Group type: EXPERIMENTAL
Intervention: Parallel‐sided posts inserted to a depth equaling the height of the crown
Number of subjects: 122
Study 33714551 — intervention group
Group type: COMPARATOR
Intervention: Contralateral molars
Number of subjects: 122
Study 32812129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with intralesional steroid (Triamcinolone acetonide)
Number of subjects: 45
Study 32812129 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser combined with intralesional botulinum toxin type A
Number of subjects: 45
Study 32812129 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG laser alone
Number of subjects: 45
Study 36243181 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Loop Stimulation (CLS) with conventional upper sensor rate programming
Number of subjects: 17
Study 36243181 — intervention group
Group type: COMPARATOR
Intervention: No rate-adaptive pacing (RAP)
Number of subjects: 17
Study 34407545 — intervention group
Group type: COMPARATOR
Intervention: 6 cycles of fludarabine, cyclophosphamide, and rituximab (FCR)
Number of subjects: 0
Study 34407545 — intervention group
Group type: EXPERIMENTAL
Intervention: Indefinite ibrutinib plus 6 cycles of rituximab (IR)
Number of subjects: 0
Study 32429961 — intervention group
Group type: EXPERIMENTAL
Intervention: Social network intervention designed to tackle loneliness
Number of subjects: 0
Study 35170392 — intervention group
Group type: EXPERIMENTAL
Intervention: Salinomycin (69 mg/kg feed)
Number of subjects: 672
Study 35170392 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated Butyrate (EB) (500 mg/kg)
Number of subjects: 672
Study 35170392 — intervention group
Group type: COMPARATOR
Intervention: Control (no dietary supplement)
Number of subjects: 672
Study 34111367 — intervention group
Group type: EXPERIMENTAL
Intervention: ActionHealthNYC program participants
Number of subjects: 0
Study 32552850 — intervention group
Group type: EXPERIMENTAL
Intervention: Unpredictable gait perturbation training (Perturb group)
Number of subjects: 21
Study 32552850 — intervention group
Group type: COMPARATOR
Intervention: Walking-only training (NonPerturb group)
Number of subjects: 21
Study 32552850 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up assessments for balance confidence and community integration
Number of subjects: 21
Study 32552850 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with perturbation training
Number of subjects: 21
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 9 h TIB
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 h TIB
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h TIB
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 h TIB
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h TIB + 1 h nap
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 h TIB + 1.5 h nap
Number of subjects: 194
Study 35089345 — intervention group
Group type: EXPERIMENTAL
Intervention: 6.5 h TIB + 1.5 h nap
Number of subjects: 194
Study 32450901 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme (5-day training including evidence-based medicine training module and application of the guideline)
Number of subjects: 26
Study 32450901 — intervention group
Group type: COMPARATOR
Intervention: Usual care (publicly available guideline)
Number of subjects: 26
Study 36240954 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated low-level red-light (RLRL) therapy
Number of subjects: 120
Study 36240954 — intervention group
Group type: COMPARATOR
Intervention: Single-vision spectacle (SVS)
Number of subjects: 120
Study 36240954 — intervention group
Group type: EXPERIMENTAL
Intervention: RLRL therapy
Number of subjects: 120
Study 33944631 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-RADS version 1.1
Number of subjects: 2813
Study 33944631 — intervention group
Group type: COMPARATOR
Intervention: Lung-RADS version 1.0
Number of subjects: 2813
Study 32173063 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 60
Study 32173063 — intervention group
Group type: COMPARATOR
Intervention: Desflurane
Number of subjects: 60
Study 35041452 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided postdilation
Number of subjects: 2325
Study 35041452 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided postdilation
Number of subjects: 2325
Study 35041452 — intervention group
Group type: COMPARATOR
Intervention: Angiography-guided without postdilation
Number of subjects: 2325
Study 35922823 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic intervention (endoscopic bulking injections)
Number of subjects: 250
Study 35922823 — intervention group
Group type: COMPARATOR
Intervention: Standard NHS surgical intervention (colposuspension, autologous fascial sling or artificial urinary sphincter)
Number of subjects: 250